Pegvisomant is a growth hormone receptor antagonist, used mainly to treat acromegaly in adults—particularly when traditional treatments like surgery, radiation, or somatostatin analogues are ineffective or unsuitable. It is grouped under the following drug class(es): Hormones. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Somavert and Trovert. Its PubChem SID is 481101796.
Pegvisomant
| CAS No | 218620‑50‑9 |
|---|---|
| Molecular Formula | C₉₉₀H₁₅₃₂N₂₆₂O₃₀₀S₇ |
| Molecular Weight | ~45,000 Da |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Pegvisomant is a growth hormone receptor antagonist, used mainly to treat acromegaly in adults—particularly when traditional treatments like surgery, radiation, or somatostatin analogues are ineffective or unsuitable.
The listed CAS number is 218620‑50‑9.
The listed molecular formula is C₉₉₀H₁₅₃₂N₂₆₂O₃₀₀S₇.
The listed molecular weight is ~45,000 Da.
The source lists Somavert and Trovert.
It is listed under Hormones.